Charles River Laboratories International (CRL) Gross Margin (2009 - 2026)
Charles River Laboratories International (CRL) posted Gross Margin of 45.02% for Q2 2026, up 15.88% on a QoQ basis from 38.85% in Q1 2026, and up 169.0% year-over-year from 16.74% in Q2 2025.
Analysis
Charles River Laboratories International (CRL) Gross Margin (2009 - 2026) Analysis & Trends
Charles River Laboratories International has reported Gross Margin for 18 years, with the latest figure at 45.02% in Q2 2026.
- On a quarterly basis, Gross Margin rose 169.0% year-over-year to 45.02% in Q2 2026; TTM through Jun 2026 was 42.15%, a 401.0% decrease from a year earlier, with the FY2025 full-year figure at 42.35%, up 27.0% from the prior year.
- Gross Margin was 45.02% for Q2 2026 at Charles River Laboratories International, up from 38.85% in the prior quarter.
- The five-year high for Gross Margin was 68.57% in Q4 2023, with the low at 34.09% in Q1 2024.
- Average Gross Margin over 5 years is 43.59%, with a median of 42.35% recorded in 2025.
- The sharpest annual moves came in 2023 and 2025: Gross Margin surged 2341 bps in 2023, then slumped 2381 bps in 2025.
- Over 5 years, Gross Margin stood at 45.16% in 2022, then soared by 52 bps to 68.57% in 2023, then retreated by 4 bps to 65.5% in 2024, then slumped by 36 bps to 41.68% in 2025, then grew by 8 bps to 45.02% in 2026.
- The last three Gross Margin figures came in at 45.02% (Q2 2026), 38.85% (Q1 2026), and 41.68% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Iqvia Holdings | 44.72 Bn | 42.64 Bn | 1.44 Bn | 32.85% |
| 2 | Medpace Holdings | 17.37 Bn | 16.87 Bn | 201.64 Mn | 28.51% |
| 3 | Icon | 13.65 Bn | 12.72 Bn | 479.29 Mn | 23.23% |
| 4 | Charles River Laboratories International | 13.13 Bn | 12.94 Bn | 452.07 Mn | 45.02% |
| 5 | Fortrea Holdings | 1.89 Bn | 1.72 Bn | 139.20 Mn | 20.52% |
| 6 | Evotec SE | 574.75 Mn | 148.87 Mn | - | - |
| 7 | Ginkgo Bioworks Holdings | 439.63 Mn | 355.09 Mn | 18.44 Mn | 91.47% |
| 8 | Champions Oncology | 69.43 Mn | 65.03 Mn | 7.70 Mn | 50.54% |
| 9 | MindWalk Holdings | 51.76 Mn | 46.29 Mn | 1.61 Mn | 58.58% |
| 10 | VivoSim Labs | 1.37 Mn | 1.37 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 27, 2026 | 45.02% |
| Mar 28, 2026 | 38.85% |
| Dec 27, 2025 | 41.68% |
| Sep 27, 2025 | 43.01% |
| Jun 28, 2025 | 43.33% |
| Mar 29, 2025 | 41.33% |
| Dec 28, 2024 | 65.50% |
| Sep 28, 2024 | 34.56% |
| Jun 29, 2024 | 34.47% |
| Mar 30, 2024 | 34.09% |
| Dec 30, 2023 | 68.57% |
| Sep 30, 2023 | 35.25% |
| Jul 1, 2023 | 37.64% |
| Apr 1, 2023 | 36.69% |
| Dec 31, 2022 | 45.16% |
| Sep 24, 2022 | 46.35% |
| Jun 25, 2022 | 46.29% |
| Mar 26, 2022 | 46.73% |
| Dec 25, 2021 | 48.28% |
| Sep 25, 2021 | 47.69% |